117 related articles for article (PubMed ID: 15868951)
1. Efficacy of two commercial preparations of interferon-alpha on human papillomavirus replication.
Sen E; McLaughlin-Drubin M; Meyers C
Anticancer Res; 2005; 25(2A):1091-100. PubMed ID: 15868951
[TBL] [Abstract][Full Text] [Related]
2. Activity and therapeutic potential of ORI-1001 antisense oligonucleotide on human papillomavirus replication utilizing a model of dysplastic human epithelium.
Alam S; Bromberg-White J; McLaughlin-Drubin M; Sen E; Bodily JM; Meyers C
Anticancer Res; 2005; 25(2A):765-77. PubMed ID: 15868908
[TBL] [Abstract][Full Text] [Related]
3. A novel drug screening assay for papillomavirus specific antiviral activity.
Clark PR; Roberts ML; Cowsert LM
Antiviral Res; 1998 Feb; 37(2):97-106. PubMed ID: 9588842
[TBL] [Abstract][Full Text] [Related]
4. The effects of interferon on the expression of human papillomavirus oncogenes.
Kim KY; Blatt L; Taylor MW
J Gen Virol; 2000 Mar; 81(Pt 3):695-700. PubMed ID: 10675406
[TBL] [Abstract][Full Text] [Related]
5. RNA-Seq Analysis of Differentiated Keratinocytes Reveals a Massive Response to Late Events during Human Papillomavirus 16 Infection, Including Loss of Epithelial Barrier Function.
Klymenko T; Gu Q; Herbert I; Stevenson A; Iliev V; Watkins G; Pollock C; Bhatia R; Cuschieri K; Herzyk P; Gatherer D; Graham SV
J Virol; 2017 Dec; 91(24):. PubMed ID: 29021401
[TBL] [Abstract][Full Text] [Related]
6. Human papillomavirus multiplex ligation-dependent probe amplification assay for the assessment of viral load, integration, and gain of telomerase-related genes in cervical malignancies.
Theelen W; Litjens RJ; Vinokurova S; Haesevoets A; Reijans M; Simons G; Smedts F; Herrington CS; Ramaekers FC; von Knebel Doeberitz M; Speel EJ; Hopman AH
Hum Pathol; 2013 Nov; 44(11):2410-8. PubMed ID: 23968641
[TBL] [Abstract][Full Text] [Related]
7. Retinoic acid and interferon-alpha effects on cell growth and differentiation in cervical carcinoma cell lines.
Yokoyama M; Nakao Y; Iwasaka T; Pater A; Sugimori H
Obstet Gynecol; 2001 Aug; 98(2):332-40. PubMed ID: 11506854
[TBL] [Abstract][Full Text] [Related]
8. HPV proteins as targets for therapeutic intervention.
Sterlinko Grm H; Banks L
Antivir Ther; 2004 Oct; 9(5):665-78. PubMed ID: 15535404
[TBL] [Abstract][Full Text] [Related]
9. The human papillomavirus E7 protein is able to inhibit the antiviral and anti-growth functions of interferon-alpha.
Barnard P; Payne E; McMillan NA
Virology; 2000 Nov; 277(2):411-9. PubMed ID: 11080488
[TBL] [Abstract][Full Text] [Related]
10. Changes in type-specific human papillomavirus load predict progression to cervical cancer.
Depuydt CE; Criel AM; Benoy IH; Arbyn M; Vereecken AJ; Bogers JJ
J Cell Mol Med; 2012 Dec; 16(12):3096-104. PubMed ID: 22978795
[TBL] [Abstract][Full Text] [Related]
11. Overriding of cyclin-dependent kinase inhibitors by high and low risk human papillomavirus types: evidence for an in vivo role in cervical lesions.
Zehbe I; Rätsch A; Alunni-Fabbroni M; Burzlaff A; Bakos E; Dürst M; Wilander E; Tommasino M
Oncogene; 1999 Apr; 18(13):2201-11. PubMed ID: 10327066
[TBL] [Abstract][Full Text] [Related]
12. Modulation of human papillomavirus type 16 mRNA in cervical invasive carcinoma patients by interferon-alpha therapy.
García-Milián R; Rios MA; Amigó M; Díaz D; Guilar O; Silveira M; Araña MJ; Perea SE
J Interferon Cytokine Res; 1996 Sep; 16(9):739-43. PubMed ID: 8887059
[TBL] [Abstract][Full Text] [Related]
13. In vitro synthesis of oncogenic human papillomaviruses requires episomal genomes for differentiation-dependent late expression.
Frattini MG; Lim HB; Laimins LA
Proc Natl Acad Sci U S A; 1996 Apr; 93(7):3062-7. PubMed ID: 8610168
[TBL] [Abstract][Full Text] [Related]
14. In vitro inhibition of SARS virus replication by human interferons.
Dahl H; Linde A; Strannegård O
Scand J Infect Dis; 2004; 36(11-12):829-31. PubMed ID: 15764169
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of the association of 13-cis-retinoic acid (13cRA) and alpha-interferon 2a (alpha-IFN 2a) in moderate-severe cervical intraepithelial neoplasia (CIN II-III): a pilot study.
Toma S; Ragni N; Raffo P; Boselli F; Gustavino C; Rugiati S; Formelli F; Palumbo R; Rosso R; De Cecco L
Anticancer Res; 1996; 16(2):931-6. PubMed ID: 8687154
[TBL] [Abstract][Full Text] [Related]
16. Infectious human papillomavirus type 31b: purification and infection of an immortalized human keratinocyte cell line.
Ozbun MA
J Gen Virol; 2002 Nov; 83(Pt 11):2753-2763. PubMed ID: 12388811
[TBL] [Abstract][Full Text] [Related]
17. Altered biology of adeno-associated virus type 2 and human papillomavirus during dual infection of natural host tissue.
Meyers C; Alam S; Mane M; Hermonat PL
Virology; 2001 Aug; 287(1):30-9. PubMed ID: 11504539
[TBL] [Abstract][Full Text] [Related]
18. Interferons and their receptors in human papillomavirus lesions of the uterine cervix.
Cintorino M; Tripodi SA; Romagnoli R; Ietta F; Ricci MG; Paulesu L
Eur J Gynaecol Oncol; 2002; 23(2):145-50. PubMed ID: 12013113
[TBL] [Abstract][Full Text] [Related]
19. CDK9 Inhibitor FIT-039 Suppresses Viral Oncogenes E6 and E7 and Has a Therapeutic Effect on HPV-Induced Neoplasia.
Ajiro M; Sakai H; Onogi H; Yamamoto M; Sumi E; Sawada T; Nomura T; Kabashima K; Hosoya T; Hagiwara M
Clin Cancer Res; 2018 Sep; 24(18):4518-4528. PubMed ID: 29712686
[No Abstract] [Full Text] [Related]
20. Physical state and expression of HPV DNA in benign and dysplastic cervical tissue: different levels of viral integration are correlated with lesion grade.
Hudelist G; Manavi M; Pischinger KI; Watkins-Riedel T; Singer CF; Kubista E; Czerwenka KF
Gynecol Oncol; 2004 Mar; 92(3):873-80. PubMed ID: 14984955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
